Project description
New perspectives into metastatic breast cancer care
Despite the emergence of advanced imaging technologies like FDG-PET/CT, response evaluation methods for metastatic breast cancer (MBC) have remained outdated for decades. This stagnation is alarming considering the profound impact accurate staging and monitoring have on treatment options and patient survival. Furthermore, the lack of patient-centric approaches exacerbates the disconnect between medical practices and the realities of living with MBC. In this context, the EU-funded PREMIO COLLAB aims to modernise response evaluation. Through a multicentre RCT, it compares FDG-PET/CT-based monitoring with conventional CT, assessing impact on survival and quality of life. It also prioritises patient perspectives, integrating participatory research to refine digital workflows. With AI-driven imaging and liquid biopsies, it promises broader insights.
Objective
PREMIO COLLAB’s vision is to prolong overall survival and improve the quality of life for patients with metastatic breast cancer (MBC) by providing refined guidance for managing response monitoring. PREMIO COLLAB strives to facilitate improved patient care and streamlined clinical workflows addressing the needs of patients, healthcare professionals, and society.
Response evaluation methods for patients with MBC have not been modernised for decades, although molecular imaging with FDG-PET/CT has emerged as a highly accurate method for staging MBC, and staging and monitoring MBC has a profound influence on treatment options and the chances of survival. Furthermore, the patient perspective has rarely been considered, although continuous response evaluation in a monitoring setting has interacted with the life of MBC patients for years. Still, no specific recommendations are provided internationally for response evaluation in MBC or in the overall management of monitoring.
PREMIO COLLAB offers complementary competencies in an interdisciplinary collaborative effort to lift this complex task. In a pragmatic multicenter randomised clinical trial (RCT), we will apply the intervention of FDG-PET/CT-based monitoring and compare it with conventional CT as state-of-the-art. The objectives are to analyse the impact of the intervention on overall survival and quality of life in patients with MBC and include cost-effectiveness analyses directly informing HTA agencies and health policymakers. Building on knowledge from the RCT, we will use participatory research designs to develop improved and modernised patient pathways and digital workflows. AI-based solutions in imaging and liquid biopsies constitute perspectives with a broader horizon.
The work will be done in multiple European centres and living labs with patient representatives, clinicians, and relevant stakeholders aiming to provide knowledge for updated recommendations with a view to subsequent clinical implementation.
This action is part of the Cancer Mission cluster of projects on ‘‘Diagnostics and Treatment (diagnostics).”
Fields of science
Programme(s)
- HORIZON.2.1 - Health Main Programme
Topic(s)
Funding Scheme
HORIZON-RIA - HORIZON Research and Innovation ActionsCoordinator
7100 Vejle
Denmark